Targeting of glycosaminoglycan-cytokine interactions as a novel therapeutic approach in allotransplantation

Transplantation

Volumn 74, Issue 5, 2002, Pages 623-629

  Fernandez Botran, Rafael ^a   Gorantla, Vijay ^a   Sun, Xichun ^a   Ren, Xiaoping ^a   Perez Abadia, Gustavo ^a   Crespo, Fabian A ^a   Oliver, Robert ^a   Orhun, Haldun I ^a   Quan, Edwin E ^a   Maldonado, Claudio ^a   Ray, Mukunda ^a   Barker, John H ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOSAMINOGLYCAN; INTERLEUKIN 8; MC2 PEPTIDE; PEPTIDE; RANTES; UNCLASSIFIED DRUG;

ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; GRAFT REJECTION; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RAT; SKIN BIOPSY; SKIN FLAP; TRANSPLANTATION;

EID: 0037106357     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200209150-00007     Document Type: Article

References (28)

1. Lindahl U, Höök M. Glycosaminoglycans and their binding to biological macromolecules. Annu Rev Biochem 1978;47:385.
2. Jackson RL, Busch SJ, Cardin AD. Glycosaminoglycans: molecular properties, protein interactions and role in physiological processes. Physiol Rev 1991;71:48.
3. Kjellen L, Lindahl A. Proteoglycans-structures and interactions. Annu Rev Biochem 1991;60:443.
4. Roberts R, Gallagher J, Spooncer E, et al. Heparan sulphate bound growth factors: a mechanism for stromal cell mediated haemopoiesis. Nature 1988;332:376.
5. Lortat-Jacob H, Grimaud JA. Interferon-γ C-terminal function: new working hypothesis. Heparan sulfate and heparin, new targets for IFN-γ protect, relax the cytokine and regulate its activity. Cell Mol Biol 1991;37:253.
6. Ramsden L, Rider CC. Selective and differential binding of interleukin (IL)-α, IL-1β, IL-2 and IL-6 to glycosaminoglycans. Eur J Immunol 1992;22:3027.
7. Tanaka Y, Adams DH, Shaw S. Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes. Immunol Today 1993;14:111.
8. Tanaka Y, Adams DH, Hubscher S, et al. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1β. Nature 1993;361:79.
9. Webb LMC, Ehrengruber MU, Clark-Lewis I, et al. Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8. Proc Natl Acad Sci USA 1993;90:7158.
10. Witt DP, Lander AD. Differential binding of chemokines to glycosaminoglycan subpopulations. Curr Biol 1994;4:394.
11. Rix DA, Douglas MS, Talbot D, et al. Role of glycosaminoglycans (GAGs) in regulation of the immunogenicity of human vascular endothelial cells. Clin Exp Immunol 1996;104:60.
12. Fernandez-Botran R, Yan J, Justus DE. Binding of interferon-γ by glycosaminoglycans: a strategy for localization and/or inhibition of its activity. Cytokine 1999;11:313.
13. McFadden G, Kelvin D. New strategies for chemokine inhibition and modulation. You take the high road and I'll take the low road. Biochem Pharmacol 1997;54:1271.
14. Mason DW, Morris PJ. Effector mechanisms in allograft rejection. Annu Rev Immunol 1986;4:119.
15. Kondo T, Novick AC, Toma H, et al. Induction of chemokine gene expression during allogeneic skin graft rejection. Transplantation 1996;61: 1750.
16. Hancock WW, Gao W, Faia KL, et al. Chemokines and their receptors in allograft rejection. Curr Opin Immunol 2000;12:511.
17. Eppley BL, Elluru R, Brock CA, et al. The epigastric fat transfer: an alternative free flap model in the rat. Ann Plastic Surg 1992;29:293.
18. Buttermeyer R, Jones NF, Min Z, et al. Rejection of the component tissues of limb allografts in rats immunosuppressed with FK-506 and cyclosporine. Plast Reconstr Surg 1996;97:139.
19. Däubener W, Nockemann S, Gutsche M, et al. Heparin inhibits the antiparasitic and immune modulatory effects of human recombinant interferon-γ. Eur J Immunol 1995;25:688.
20. Douglas MS, Rix DA, Dark JH, et al. Examination of the mechanism by which heparin antagonizes activation of a model endothelium by interferon-γ (IFN-γ). Clin Exp Immunol 1997;107:578.
21. Yard BA, Lorentz CP, Herr D, et al. Sulfation-dependent down-regulation of interferon-γ-induced major histocompatibility complex class I and II and intracellular adhesion molecule-1 expression on tubular and endothelial cells by glycosaminoglycans. Transplantation 1998;66:1244.
22. Lider O, Baharav E, Mekroy YA. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J Clin Invest 1989;83:752.
23. Ekre HPT, Naparstek Y, Lider O. Anti-inflammatory effects of heparin and its derivatives: inhibition of complement and lymphocyte migration. Adv Exp Med Biol 1992;313:329.
24. Nelson RM, Cecconi O, Roberts WG, et al. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993;82:3253.
25. Evans RC, Wong VS, Morris AI, et al. Treatment of corticosteroid-resistant ulcerative colitis with heparin: a report of 16 cases. Aliment Pharmacol Ther 1997;11:1037.
26. Oravecz T, Pall M, Wang J, et al. Regulation of anti-HIV-1 activity of RANTES by heparan sulfate proteoglycans. J Immunol 1997;159:4587.
27. Petersen F, Bock L, Flad HD, et al. A chondroitin sulfate proteoglycan on human neutrophils specifically binds platelet factor 4 and is involved in cell activation. J Immunol 1998;161:4347.
28. Ali S, Palmer ACV, Banerjee B, et al. Examination of the function of RANTES, MIP-1α, and MIP-1β following interaction with heparin-like glycosaminoglycans. J Biol Chem 2000;275:11721.